Literature DB >> 10093942

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.

H C Meissner1, R C Welliver, S A Chartrand, B J Law, L E Weisman, H L Dorkin, W J Rodriguez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10093942     DOI： 10.1097/00006454-199903000-00004

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


× No keyword cloud information.
  19 in total

1.  Targeting pili in enterococcal pathogenesis.

Authors:  Kenneth L Pinkston; Kavindra V Singh; Peng Gao; Nathaniel Wilganowski; Holly Robinson; Sukhen Ghosh; Ali Azhdarinia; Eva M Sevick-Muraca; Barbara E Murray; Barrett R Harvey
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

2.  Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

Authors: 
Journal:  Paediatr Child Health       Date:  1999-10       Impact factor: 2.253

Review 3.  mRNA: A Novel Avenue to Antibody Therapy?

Authors:  Thomas Schlake; Moritz Thran; Katja Fiedler; Regina Heidenreich; Benjamin Petsch; Mariola Fotin-Mleczek
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

Review 4.  New insights for development of a safe and protective RSV vaccine.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Kari Ann Shirey; Gregory A Prince; Stefanie N Vogel
Journal:  Hum Vaccin       Date:  2010-06-01

5.  Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase.

Authors:  Michel Liuzzi; Stephen W Mason; Mireille Cartier; Carol Lawetz; Robert S McCollum; Nathalie Dansereau; Gordon Bolger; Nicole Lapeyre; Yvon Gaudette; Lisette Lagacé; Marie-Josée Massariol; Florence Dô; Paul Whitehead; Lyne Lamarre; Erika Scouten; Josée Bordeleau; Serge Landry; Jean Rancourt; Gulrez Fazal; Bruno Simoneau
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Authors:  Dai Wang; Shannon Phan; Daniel J DiStefano; Michael P Citron; Cheryl L Callahan; Lani Indrawati; Sheri A Dubey; Gwendolyn J Heidecker; Dhanasekaran Govindarajan; Xiaoping Liang; Biao He; Amy S Espeseth
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

7.  Predicting outcome in ex-premature infants supported with extracorporeal membrane oxygenation for acute hypoxic respiratory failure.

Authors:  K L Brown; G Walker; D J Grant; K Tanner; D A Ridout; L S Shekerdemian; J H Smith; C Davis; R K Firmin; A P Goldman
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-09       Impact factor: 5.747

8.  Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.

Authors:  Arun K Kashyap; John Steel; Adam Rubrum; Angeles Estelles; Raffaella Briante; Natalia A Ilyushina; Li Xu; Ryann E Swale; Aleksandr M Faynboym; Pamela K Foreman; Michael Horowitz; Lawrence Horowitz; Richard Webby; Peter Palese; Richard A Lerner; Ramesh R Bhatt
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

9.  The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Authors:  Mao Kinoshita; Hideya Kato; Hiroaki Yasumoto; Masaru Shimizu; Saeko Hamaoka; Yoshifumi Naito; Koichi Akiyama; Kiyoshi Moriyama; Teiji Sawa
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

10.  Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.

Authors:  Caroline Fenton; Lesley J Scott; Greg L Plosker
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.